Etubics Will Present Results Of Its Colorectal Cancer Phase 1 And 2 Immunotherapy Trial At The Annual American Society of Clinical Oncology Meeting In Chicago
5/29/2014 7:04:46 AM
Etubics Corporation, a clinical stage biotechnology company with a proprietary platform technology that delivers a long lasting "active" immune response against diseases, will present clinical data from its Phase 1/2 proof of concept clinical trials using an immunotherapeutic to treat patients with metastatic colorectal cancer or mCRC at the Annual American Society of Clinical Oncology (ASCO) Meeting in Chicago on Sunday, June 1st, 2014 during the Developmental Therapeutics Immunotherapy session from 8:00 a.m. to 11:45 a.m.
Help employers find you! Check out all the jobs and post your resume.
comments powered by